When and How to Publish Results on Clinical Trial Registries

Why Posting Trial Results Is a Regulatory Requirement

Results disclosure on public registries is not optional—it’s a mandated obligation governed by regulations such as FDAAA 801, EU Regulation 536/2014, and WHO best practices. Regulatory bodies like the FDA, EMA, and WHO expect timely posting of summary results to promote data transparency and uphold ethical standards for participant protection.

Failure to post results within the designated timeframe may lead to noncompliance notices, fines, rejection of future submissions, and reputational damage. Sponsors, investigators, and CROs all have defined responsibilities when it comes to registry result postings.

Deadlines for Results Posting on Different Registries

Each major trial registry has defined rules for the timing of results posting:

• ClinicalTrials.gov (USA): Summary results must be posted within 12 months of the “primary completion date.” Fines can exceed $10,000/day for non-compliance.
• EudraCT (EU legacy): Summary results must be posted within 12 months (or 6 months for pediatric trials) of trial end. Applies to trials under Directive 2001/20/EC.
• CTIS (EU CTR 536/2014): Same 12-month rule applies, but results are posted directly in CTIS workspace with new transparency controls.
• WHO ICTRP-linked registries: Generally aligned with WHO best practice guidance (12 months for summary disclosure).

It’s vital to track “primary completion” and “end-of-trial” definitions in the protocol, as these dates trigger posting obligations. Failure to recognize the right deadline often leads to unintentional non-compliance.

Essential Elements of Summary Results Submissions

Results posted to registries must adhere to standardized formats. While each registry has specific templates, most include:

• Participant Flow (including number enrolled, completed, withdrawn)
• Baseline Characteristics (age, sex, condition)
• Primary and Secondary Outcome Data
• Adverse Events Summary
• Statistical Analysis Description

For example, ClinicalTrials.gov requires a tabular display using XML format or results entry via PRS system, while CTIS accepts Word and PDF templates but may eventually move to structured data input. Tools like FDA’s ClinicalTrials.gov results templates can be used for consistency.

How to Format and Submit Results on ClinicalTrials.gov

Submission of results on ClinicalTrials.gov involves several steps via the PRS (Protocol Registration and Results System):

1. Login using your organization’s PRS account
2. Locate the trial (NCT number) under “Records”
3. Navigate to “Results Section” and enter all tabs (Participant Flow, Baseline, Outcome, AE)
4. Validate and fix errors as prompted by system checks
5. Mark the record as “Ready for Review”
6. Submit for QC review and track the submission status

Validation errors must be cleared before the record moves into the public domain. FDA recommends that sponsors allocate 3–4 weeks for this full cycle, including corrections.

How to Post Results in EudraCT and CTIS

For legacy trials under EudraCT, sponsors must use the EudraCT results submission portal and upload:

• XML summary results file
• Validator output (EMA XML validation tool)
• PDF with results, if applicable

In CTIS, the process differs. The Clinical Trial Sponsor Workspace allows direct upload of results documents in a specific trial folder. CTIS tracks each submission milestone and will issue system-level flags for missing documents or overdue timelines.

To read more on how CTIS compares with legacy EU registry systems, visit PharmaRegulatory.in.

Best Practices for Timely and Accurate Results Posting

Maintaining registry compliance is easier when sponsors adopt proactive practices. Some industry-tested strategies include:

• Develop an SOP that defines the responsibilities and timelines for results posting, especially highlighting roles for Data Management, Medical Writing, and Regulatory Affairs.
• Use results tracker tools to monitor upcoming deadlines and overdue postings across registries.
• Assign registry accountability to a single owner or team (e.g., Regulatory Operations or Clinical QA).
• Validate results content internally before registry upload to avoid errors and rejections.
• Capture confirmation emails/screenshots after successful posting for audit readiness.

Establishing these workflows early ensures consistency in multi-center or global trials where varying jurisdictional requirements must be harmonized.

Common Pitfalls and How to Avoid Them

Sponsors often encounter issues during results submission due to lack of internal controls. Common pitfalls include:

• Missing the deadline due to misidentification of trial completion dates
• Inadequate data formatting (e.g., decimals, confidence intervals)
• Non-conformance with registry templates
• Duplicate records or conflicting data between CTD and registry
• Failure to update record post-results (e.g., status, links)

These issues not only delay compliance but also create audit risks. Training staff and using mock QC checks of registry data can significantly reduce these failures.

Audit Trail and Documentation for Result Submissions

During inspections, regulatory authorities like the EMA and FDA may request evidence of when and how results were posted. Therefore, maintaining a robust audit trail is essential.

• Keep PDF printouts of the results page with date stamps
• Save validator output files (EudraCT) and XML versions (ClinicalTrials.gov)
• Maintain email confirmation from registry system
• Document internal QC checks and approval logs

This documentation should be filed in the TMF under the “Registry and Public Disclosure” section or within an eTMF with traceability metadata.

Conclusion

Posting clinical trial results is a legally binding requirement that reflects the sponsor’s commitment to transparency and compliance. From understanding timelines to mastering the formatting and submission processes across various registries, trial sponsors must integrate disclosure planning into every protocol lifecycle.

Adhering to global registry standards and maintaining comprehensive documentation helps prevent audit findings, regulatory delays, and reputational harm. To learn more about global trial disclosure workflows and access SOP templates, visit PharmaValidation.in or explore WHO publication guidelines at WHO.int.

Comparing FDAAA and EU CTR: A Deep Dive into Trial Disclosure Regulations

Introduction: Why Understanding These Differences Matters

With increasing globalization of clinical research, sponsors often conduct trials in both the United States and the European Union. Understanding the distinctions between the U.S. FDAAA 801 Final Rule and the EU Clinical Trials Regulation (CTR) is critical to ensuring full compliance and avoiding penalties.

Though both frameworks share a common objective—to ensure timely and public access to clinical trial data—they differ significantly in structure, implementation, reporting timelines, and enforcement. Misalignment can lead to regulatory breaches, funding rejections, or ethical concerns. This article outlines the key contrasts and offers a side-by-side view of what sponsors must know.

Disclosure Scope: What Trials Are Covered?

FDAAA 801 applies to “Applicable Clinical Trials” (ACTs), including controlled clinical investigations (other than Phase I) of FDA-regulated drugs, biological products, and devices. Exemptions include Phase I trials and small feasibility studies for devices.

EU CTR, on the other hand, applies to all interventional trials on medicinal products intended for human use conducted in at least one EU/EEA Member State. This includes Phase I trials, pediatric studies, and bioequivalence trials, which are often excluded from FDAAA’s disclosure scope.

Registration Requirements and Timelines

Under FDAAA, trial registration must occur no later than 21 days after the enrollment of the first participant. Registration includes details such as sponsor name, conditions studied, eligibility criteria, outcomes, and locations.

With the EU CTR, registration must happen prior to the trial start, meaning before the first subject is enrolled. This mandatory prospective registration ensures full transparency from the outset.

Moreover, the EU CTR uses a single-entry system—CTIS—making it easier to track compliance. In contrast, ClinicalTrials.gov allows sponsors to manage studies independently with fewer centralized controls.

Result Disclosure Timelines and Content

One of the most notable differences lies in result submission:

• FDAAA 801: Results must be posted within 12 months of the primary completion date.
• EU CTR: Results must be posted within 12 months of the end of the trial. Pediatric studies require reporting within 6 months.

Additionally, the EU CTR mandates Lay Summaries written in plain language and public availability of the protocol and assessment reports post-study. FDAAA does not require lay summaries, although structured result tables and adverse event data are mandatory.

Data Elements and Registry Structure

Both registries require similar core data—such as trial phase, interventions, and endpoints—but differ in their formats and user interfaces:

Public Access to Information and Redactions

CTIS enables automatic publication of key documents, including protocol synopsis, investigator brochures, and assessment reports. It uses a deferral system to delay publication of sensitive commercial data, but full disclosure is the default.

ClinicalTrials.gov provides structured tabular result data and allows public access but does not release full protocols or supporting documents unless added manually. The redaction process is sponsor-controlled.

Adverse Event Reporting

Under FDAAA, sponsors must submit structured Serious and Non-Serious Adverse Events in tabular format. These include frequency thresholds (e.g., ≥5%) and system-organ classification. Events are categorized by arm and severity.

In contrast, the EU CTR integrates adverse event summaries into the broader study report structure. While less tabular, it includes narrative-level data and often overlaps with EudraVigilance safety reporting.

Legal Penalties and Enforcement Mechanisms

FDAAA violations are subject to civil monetary penalties. In 2025, the fine stands at $13,237 per day of noncompliance. The FDA publicly lists sponsors who fail to report required data. NIH-funded researchers may lose grant eligibility.

The EU CTR enforces penalties at the Member State level. These may include trial suspension, ethics committee action, or rejection of future applications. EMA audits the CTIS system for systemic noncompliance and supports corrective actions.

Multinational Trial Considerations

When conducting global trials, sponsors must comply with both FDAAA and EU CTR concurrently. This means dual registry management—using both ClinicalTrials.gov and CTIS—and aligning timelines. The use of Clinical Trial Management Systems (CTMS) integrated with registry APIs is recommended to synchronize submissions.

For example, a U.S.-based sponsor enrolling in Germany must register in CTIS before the trial starts there, while still registering on ClinicalTrials.gov within 21 days of enrolling the first U.S. participant.

Case Study: Reporting a Pediatric Oncology Trial

A Phase II pediatric oncology trial conducted in both the U.S. and France offers insight:

• In the U.S., the sponsor reported results 12 months after primary completion using ClinicalTrials.gov. Lay summaries and protocols were not disclosed.
• In France, the same trial was submitted to CTIS and required both technical and lay summaries, protocol disclosure, and public posting of the assessment report within 6 months of completion.

This example highlights the additional transparency obligations under the EU CTR, especially for pediatric studies.

Summary: Aligning Global Disclosure Strategies

While FDAAA and EU CTR share common goals of trial transparency, their implementation differs. Sponsors must:

• Track and comply with jurisdiction-specific timelines
• Ensure dual registration for multinational trials
• Prepare lay summaries for EU trials
• Use structured templates and automated systems for compliance

Failure to do so can result in reputational damage, financial penalties, and even legal action. Harmonizing regulatory strategy is no longer optional—it is a core function of ethical and operational trial conduct.